Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 5 | Orphanet Journal of Rare Diseases

Figure 5

From: Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis

Figure 5

Cysteamine disrupts production of normal human bronchial epithelial (NHBE) cell-derived mucus. Differentiated NHBE monolayers were exposed (basally) to 1 mg/ml cysteamine or control culture media for 7 days. Mucin production at the apical aspect was then assessed by Alcian blue staining macro- and microscopically (panels A & B) and the amount of free, non-mucin bound airway surface fluid quantified (panel C).

Back to article page